S'abonner

Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes - 30/03/13

Doi : 10.1016/j.jaci.2012.05.036 
Yvonne R. Chan, MD a, , Kong Chen, PhD b, Steven R. Duncan, MD a, Kira L. Lathrop, MAMS c, Joseph D. Latoche, BS a, Alison J. Logar, BS b, Derek A. Pociask, PhD b, Brendon J. Wahlberg, MS a, Prabir Ray, PhD a, Anuradha Ray, PhD a, Joseph M. Pilewski, MD a, Jay K. Kolls, MD b
a Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pa 
c Eye and Ear Institute, University of Pittsburgh, Pittsburgh, Pa 
b Richard King Mellon Foundation Institute for Pediatric Research, Children’s Hospital of Pittsburgh, Pittsburgh, Pa 

Corresponding author: Yvonne R. Chan, MD, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, 3459 Fifth Avenue, NW 628 MUH, Pittsburgh, PA 15213.

Abstract

Background

IL-17 is an important cytokine signature of the TH differentiation pathway TH17. This T-cell subset is crucial in mediating autoimmune disease or antimicrobial immunity in animal models, but its presence and role in human disease remain to be completely characterized.

Objective

We set out to determine the frequency of TH17 cells in patients with cystic fibrosis (CF), a disease in which there is recurrent infection with known pathogens.

Methods

Explanted lungs from patients undergoing transplantation or organ donors (CF samples = 18; non-CF, nonbronchiectatic samples = 10) were collected. Hilar nodes and parenchymal lung tissue were processed and examined for TH17 signature by using immunofluorescence and quantitative real-time PCR. T cells were isolated and stimulated with antigens from Pseudomonas aeruginosa and Aspergillus species. Cytokine profiles and staining with flow cytometry were used to assess the reactivity of these cells to antigen stimulation.

Results

We found a strong IL-17 phenotype in patients with CF compared with that seen in control subjects without CF. Within this tissue, we found pathogenic antigen–responsive CD4+IL-17+ cells. There were double-positive IL-17+IL-22+ cells [TH17(22)], and the IL-22+ population had a higher proportion of memory characteristics. Antigen-specific TH17 responses were stronger in the draining lymph nodes compared with those seen in matched parenchymal lungs.

Conclusion

Inducible proliferation of TH17(22) with memory cell characteristics is seen in the lungs of patients with CF. The function of these individual subpopulations will require further study regarding their development. T cells are likely not the exclusive producers of IL-17 and IL-22, and this will require further characterization.

Le texte complet de cet article est disponible en PDF.

Key words : TH17, TH22, IL-17, IL-22, cystic fibrosis, Pseudomonas species, Aspergillus species, chronic infectious disease, memory T-cell response, lung transplant

Abbreviations used : Asp, CF, Con A, COPD, CORE, DLN, NK, Pa(EL), Pa(LL), PLC, ROR, TCR


Plan


 Supported by research grants from the National Heart, Lung, and Blood Institute, National Institutes of Health (K08 HL089189 to Y.R.C. and P50 HL084932 to J.K.K. and J.M.P.), the Howard Hughes Medical Institute (Early Career Physician Scientist Award to Y.R.C.), the CF Foundation (to J.M.P.), and Novartis (to J.K.K. and J.M.P.). Also supported by the confocal imaging resources of the Core Grant for Vision Research at the University of Pittsburgh (NIH P30-EY08098).
 Disclosure of potential conflict of interest: Y. R. Chan has received research support from the Howard Hughes Medical Institute and the National Institutes of Health (NIH) and has received payment from Novartis for contract performance of experiments. S. R. Duncan and K. Lathrop have received research support from the NIH. J. M. Pilewski has received research support from the Cystic Fibrosis Foundation and the NIH. J. K. Kolls has received research support from the NIH, is chair of the board for MiniVax, is coinventor on a patent submitted by Louisiana State University Health Sciences Center, and has received travel compensation from MiniVax. The rest of the authors declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 4

P. 1117 - avril 2013 Retour au numéro
Article précédent Article précédent
  • Vitamin D insufficiency is associated with challenge-proven food allergy in infants
  • Katrina J. Allen, Jennifer J. Koplin, Anne-Louise Ponsonby, Lyle C. Gurrin, Melissa Wake, Peter Vuillermin, Pamela Martin, Melanie Matheson, Adrian Lowe, Marnie Robinson, Dean Tey, Nicholas J. Osborne, Thanh Dang, Hern-Tze Tina Tan, Leone Thiele, Deborah Anderson, Helen Czech, Jeeva Sanjeevan, Giovanni Zurzolo, Terence Dwyer, Mimi L.K. Tang, David Hill, Shyamali C. Dharmage
| Article suivant Article suivant
  • Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22)
  • Gary Y.J. Chew, Umang Sinha, Paul A. Gatenby, Theo DeMalmanche, Stephen Adelstein, Roger Garsia, Pravin Hissaria, Martyn A. French, Anastasia Wilson, Belinda Whittle, Philippa Kirkpatrick, D. Sean Riminton, David A. Fulcher, Matthew C. Cook

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.